TFF Pharmaceuticals (NASDAQ:TFFP) Releases Earnings Results, Beats Expectations By $0.05 EPS

TFF Pharmaceuticals (NASDAQ:TFFP – Get Rating) issued its earnings results on Wednesday. The company reported ($0.33) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.38) by $0.05, MarketWatch Earnings reports. TFF Pharmaceuticals had a negative return on equity of 61.58% and a negative net margin of 35,272.73%. During the same period in the previous year, the company posted ($0.33) earnings per share.

NASDAQ TFFP traded up $0.13 during mid-day trading on Thursday, reaching $4.12. The stock had a trading volume of 191,191 shares, compared to its average volume of 155,825. TFF Pharmaceuticals has a 1 year low of $3.60 and a 1 year high of $12.28. The stock has a market cap of $104.53 million, a PE ratio of -3.30 and a beta of 2.14. The company has a fifty day moving average price of $5.94 and a 200 day moving average price of $6.79.

In other news, Director Aaron G.L. Fletcher acquired 542,000 shares of TFF Pharmaceuticals stock in a transaction that occurred on Monday, April 4th. The shares were bought at an average cost of $6.47 per share, with a total value of $3,506,740.00. Following the transaction, the director now directly owns 100,000 shares of the company’s stock, valued at approximately $647,000. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 9.90% of the company’s stock.

Several institutional investors have recently modified their holdings of the company. Stifel Financial Corp raised its holdings in TFF Pharmaceuticals by 31.8% during the 4th quarter. Stifel Financial Corp now owns 14,500 shares of the company’s stock worth $129,000 after buying an additional 3,500 shares during the period. Morgan Stanley boosted its position in shares of TFF Pharmaceuticals by 69.8% in the second quarter. Morgan Stanley now owns 29,209 shares of the company’s stock valued at $281,000 after acquiring an additional 12,003 shares during the period. Goldman Sachs Group Inc. purchased a new position in shares of TFF Pharmaceuticals during the fourth quarter worth approximately $118,000. State Street Corp increased its position in TFF Pharmaceuticals by 47.4% during the 4th quarter. State Street Corp now owns 64,678 shares of the company’s stock valued at $574,000 after purchasing an additional 20,800 shares during the period. Finally, Geode Capital Management LLC boosted its stake in TFF Pharmaceuticals by 41.1% in the 4th quarter. Geode Capital Management LLC now owns 175,969 shares of the company’s stock worth $1,560,000 after purchasing an additional 51,268 shares in the last quarter. Institutional investors and hedge funds own 18.28% of the company’s stock.

TFFP has been the subject of several research analyst reports. Zacks Investment Research cut TFF Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, March 30th. B. Riley reduced their price objective on TFF Pharmaceuticals from $24.00 to $18.00 and set a “buy” rating on the stock in a research note on Tuesday, March 29th.

TFF Pharmaceuticals Company Profile (Get Rating)

TFF Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions.

Featured Stories